Prostate Cancer Coverage from Every Angle

Are Researchers Closer to Diagnosing Aggressive Prostate Cancer at an Early Stage?

By: Hillary Ojeda
Posted: Monday, October 15, 2018

Although there’s still no way to diagnose aggressive prostate cancer at an early stage, a team of Scandinavian researchers may have taken a step in the right direction. In a study published in the International Journal of Cancer, lead author Johanna Schleutker, PhD, of the University of Turku, Finland, and colleagues reported that ANO7  is a possible prostate cancer susceptibility gene.

“One of the current biggest unmet needs in prostate cancer care is being able to diagnose aggressive cancers at an early stage,” said Professor Schleutker in a University of Turku press release. “Genetic testing for ANO7  could help identify these patients sooner and may bring new opportunities for precision oncology in prostate cancer.”

In a search for genetic mutations associated with the disease, the researchers analyzed the DNA of 1,769 patients with prostate cancer and 1,711 healthy men. They identified two pathogenic variants of ANO7  that could be used in testing. Their data showed one mutation (high AN07  expression) was linked to poor survival, and the other mutation correlated with an increased risk of developing prostate cancer as well as the severity of the disease.

According to the authors, AN07  belongs to the anoctamin family of membrane proteins and is specifically expressed in the prostate. They believe their findings “should spur further research to elucidate the regulatory networks of AN07.”

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.